Article Text

Download PDFPDF
Fifteen-minute guide to managing oligoarticular juvenile idiopathic arthritis
  1. Dearbhla McKenna1,
  2. Diarmuid McLaughlin2,
  3. Cathy Campbell1,
  4. Melissa Mulholland3,
  5. Andrew Thompson3,
  6. Clare Loughran3,
  7. Paul Jackson1,
  8. Madeleine Rooney4
  1. 1 Paediatric Rheumatology, Musgrave Park Hospital, Belfast, UK
  2. 2 Neonatology, Royal Jubilee Maternity Service, Belfast, UK
  3. 3 General Paediatrics, Royal Belfast Hospital for Sick Children, Belfast, UK
  4. 4 Centre for Infection and Immunity, QUB, Belfast, UK
  1. Correspondence to Dr Cathy Campbell, Musgrave Park Hospital, Belfast, Antrim BT9 7JB, UK; ccampbell44{at}


Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease affecting children and young people today. However, it is not a single disease entity, but an umbrella term that gathers together a heterogeneous collection of complex, chronic inflammatory conditions with oligoarticular JIA the most common form in both Europe and North America. Due to its relative rarity in daily practice and potential to mimic other conditions, oligoarticular JIA can present a diagnostic and management challenge to healthcare professionals in both primary care and general paediatrics. The aim of this article is to provide a summary of the key aspects of diagnosis, investigation and management of this condition, with the hopes of building clinicians’ confidence when facing a possible case of oligoarticular JIA.

  • rheumatology
  • therapeutics

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Correction notice This paper has been updated since it was published online. The table legends have been inserted.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.